“Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE”. Science286 (5440): 735–41. (Oct 1999). doi:10.1126/science.286.5440.735. PMID10531052.
“Alzheimer therapeutics-what after the cholinesterase inhibitors?”. Age and Ageing35 (4): 332–5. (Jul 2006). doi:10.1093/ageing/afl009. PMID16644763.
“2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead”. Journal of Medicinal Chemistry50 (18): 4261–4. (Sep 2007). doi:10.1021/jm0705408. PMID17685503.
“Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE”. Science286 (5440): 735–41. (Oct 1999). doi:10.1126/science.286.5440.735. PMID10531052.
“Alzheimer therapeutics-what after the cholinesterase inhibitors?”. Age and Ageing35 (4): 332–5. (Jul 2006). doi:10.1093/ageing/afl009. PMID16644763.
“2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead”. Journal of Medicinal Chemistry50 (18): 4261–4. (Sep 2007). doi:10.1021/jm0705408. PMID17685503.
“BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics”. Human Molecular Genetics10 (12): 1317–24. (Jun 2001). doi:10.1093/hmg/10.12.1317. PMID11406613.